|
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[2] LI J,HUANG L,YAN J,et al. Liver resection for hepatocellular carcinoma:Personal experiences in a series of 1330 consecutive cases in China[J]. ANZ J Surg,2018,88(10):e713-e717.
|
|
[3] MARUBASHI S,GOTOH K,AKITA H,et al. Anatomical versus non-anatomical resection for hepatocellular carcinoma[J]. Br J Surg,2015,102(7):776-784.
|
|
[4] LU PH,NEGRIN RS. A novel population of expanded human CD3+CD56+cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency[J]. J Immunol,1994,153(4):1687-1696.
|
|
[5] LINN YC,LAU SK,LIU BH,et al. Characterization of the recognition and functional heterogeneity exhibited by cytokineinduced killer cell subsets against acute myeloid leukaemia target cell[J]. Immunology,2009,126(3):423-435.
|
|
[6] PAN QZ,LIU Q,ZHOU YQ,et al. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma[J]. Cancer Immunol Immunother,2020,69(5):825-834.
|
|
[7] LEE JH,LEE JH,LIM YS,et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology,2015,148(7):1383-1391.
|
|
[8] LEE JH,LEE JH,LIM YS,et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma:An extended 5-year follow-up[J].Cancer Immunol Immunother,2019,68(1):23-32.
|
|
[9] YOON JS,SONG BG,LEE JH,et al. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma:A propensity score-matched analysis of real-world data[J].BMC Cancer,2019,19(1):523.
|
|
[10] YU SJ,MA C,HEINRICH B,et al. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma[J]. J Hepatol,2019,70(3):449-457.
|
|
[11] ZHANG J,WU N,LIAN Z,et al. The combined antitumor effects of(125)I radioactive particle implantation and cytokine-induced killer cell therapy on xenograft hepatocellular carcinoma in a mouse model[J]. Technol Cancer Res Treat,2017,16(6):1083-1091.
|
|
[12] HUANG F,WANG B,ZENG J,et al. MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells[J]. Oncol Lett,2018,15(4):4797-4804.
|
|
[13] CHEN M,XU M,ZHU C,et al. Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model[J]. Cancer Immunol Immunother,2019,68(6):961-971.
|
|
[14] CHOI JW,LEE ES,KIM SY,et al. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes(MYJ1633)against liver cancer[J]. BMC Cancer,2019,19(1):817.
|
|
[15] PARKHURST MR,RILEY JP,DUDLEY ME,et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression[J]. Clin Cancer Res,2011,17(19):6287-6297.
|
|
[16] SAKAMOTO N,ISHIKAWA T,KOKURA S,et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer[J]. J Transl Med,2015,13:277.
|
|
[17] MILLER JS,SOIGNIER Y,PANOSKALTSIS-MORTARI A,et al.Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer[J]. Blood,2005,105(8):3051-3057.
|
|
[18] QIN Z,CHEN J,ZENG J,et al. Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma:A preliminary clinical study[J]. Cancer Biol Ther,2017,18(5):323-330.
|
|
[19] YANG Y,QIN Z,DU D,et al. Safety and short-term efficacy of irreversible electroporation and allogenic natural killer cell immunotherapy combination in the treatment of patients with unresectable primary liver cancer[J]. Cardiovasc Intervent Radiol,2019,42(1):48-59.
|
|
[20] XIE S,WU Z,ZHOU L,et al. Iodine-125 seed implantation and allogenic natural killer cell immunotherapy for hepatocellular carcinoma after liver transplantation:A case report[J].Onco Targets Ther,2018,11:7345-7352.
|
|
[21] EL ANSARY M,MOGAWER S,ELHAMID SA,et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol,2013,139(1):39-48.
|
|
[22] JUNG NC,LEE JH,CHOI HJ,et al. Dendritic cell immunotherapy combined with cytokine-induced killer cells effectively suppresses established hepatocellular carcinomas in mice[J]. Immunol Invest,2016,45(6):553-565.
|
|
[23] CAO J,KONG FH,LIU X,et al. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma:A meta-analysis[J]. World J Gastroenterol,2019,25(27):3649-3663.
|
|
[24] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
|
|
[25] ZHOU Z,QIN H,WENG L,et al. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma[J]. J BUON,2019,24(2):615-621.
|
|
[26] HE G,ZHENG C,HUO H,et al. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma:A meta-analysis[J]. Int Immunopharmacol,2016,40:436-442.
|
|
[27] ZHANG J,LI H,GAO D,et al. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE[J]. Cancer Biol Ther,2018,19(6):475-483.
|
|
[28] MA YJ,HE M,HAN JA,et al. A clinical study of HBs Ag-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B[J]. Scand J Immunol,2013,78(4):387-393.
|
|
[29] ZHOU P,LIANG P,DONG B,et al. PhaseⅠclinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma[J]. Cancer Biol Ther,2011,11(5):450-456.
|
|
[30] DUDLEY ME,GROSS CA,SOMERVILLE RP,et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma[J]. J Clin Oncol,2013,31(17):2152-2159.
|
|
[31] BEN-AVI R,ITZHAKI O,SIMANSKY D,et al. Metastatic lung lesions as a preferred resection site for immunotherapy with tumor infiltrating lymphocytes[J]. J Immunother,2016,39(5):218-222.
|
|
[32] DONIA M,LARSEN SM,MET O,et al. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor[J]. Cytotherapy,2014,16(8):1117-1120.
|
|
[33] TAVERA RJ,FORGET MA,KIM YU,et al. Utilizing T-cell activation signals 1,2,and 3 for tumor-infiltrating lymphocytes(TIL)expansion:The advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma[J]. J Immunother,2018,41(9):399-405.
|
|
[34] YUNGER S,BAR EL A,ZELTZER LA,et al. Tumor-infiltrating lymphocytes from human prostate tumors reveal antitumor reactivity and potential for adoptive cell therapy[J]. Oncoimmunology,2019,8(12):e1672494.
|
|
[35] WANG Y,CHEN H,WU M,et al. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes[J]. Chin Med J(Engl),1997,110(2):114-117.
|
|
[36] ROSENBERG SA,SPIESS P,LAFRENIERE R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes[J]. Science,1986,233(4770):1318-1321.
|
|
[37] CHANDRAN SS,SOMERVILLE R,YANG JC,et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes:A single-centre,two-stage,single-arm,phase 2 study[J]. Lancet Oncol,2017,18(6):792-802.
|
|
[38] NGUYEN LT,SAIBIL SD,SOTOV V,et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and lowdose interleukin-2[J]. Cancer Immunol Immunother,2019,68(5):773-785.
|
|
[39] JIANG SS,TANG Y,ZHANG YJ,et al. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma[J]. Oncotarget,2015,6(38):41339-41349.
|
|
[40] GAO H,LI K,TU H,et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res,2014,20(24):6418-6428.
|
|
[41] JIANG Z,JIANG X,CHEN S,et al. Anti-GPC3-CAR T cells suppress the growth of tumor cells in patient-derived xenografts of hepatocellular carcinoma[J]. Front Immunol,2016,7:690.
|
|
[42] PAN Z,DI S,SHI B,et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein[J]. Cancer Immunol Immunother,2018,67(10):1621-1634.
|
|
[43] GUO X,JIANG H,SHI B,et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma[J]. Front Pharmacol,2018,9:1118.
|
|
[44] LIU Y,DI S,SHI B,et al. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma[J]. J Immunol,2019,203(1):198-207.
|
|
[45] BATRA SA,RATHI P,GUO L,et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma[J]. Cancer Immunol Res,2020,8(3):309-320.
|
|
[46] ADACHI K,KANO Y,NAGAI T,et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J]. Nat Biotechnol,2018,36(4):346-351.
|
|
[47] WEI WY,BEICHENG S. Anti-GPC3 CAR-T therapy suppresses hepatocarcinoma and IL7 and CCL19 expression enhanced the infiltration of CAR-T cells in tumor[J]. HPB,2019,21:s403.
|
|
[48] LIU H,XU Y,XIANG J,et al. Targeting alpha-fetoprotein(AFP)-MHC complex with CAR T-cell therapy for liver cancer[J]. Clin Cancer Res,2017,23(2):478-488.
|
|
[49] ENBLAD G,KARLSSON H,GAMMELGRD G,et al. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia[J]. Clin Cancer Res,2018,24(24):6185-6194.
|
|
[50] GILL S,JUNE CH. Going viral:Chimeric antigen receptor Tcell therapy for hematological malignancies[J]. Immunol Rev,2015,263(1):68-89.
|
DownLoad: